Metropolitan Life Insurance Co. NY cut its position in shares of Natus Medical Inc (NASDAQ:BABY) by 58.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,873 shares of the medical equipment provider’s stock after selling 13,864 shares during the quarter. Metropolitan Life Insurance Co. NY’s holdings in Natus Medical were worth $377,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its stake in Natus Medical by 3.3% during the third quarter. Dimensional Fund Advisors LP now owns 1,604,876 shares of the medical equipment provider’s stock worth $60,183,000 after purchasing an additional 51,938 shares during the last quarter. Millennium Management LLC bought a new position in Natus Medical during the fourth quarter worth $10,445,000. WCM Investment Management CA lifted its stake in Natus Medical by 503.8% during the fourth quarter. WCM Investment Management CA now owns 267,850 shares of the medical equipment provider’s stock worth $10,232,000 after purchasing an additional 223,490 shares during the last quarter. Cambiar Investors LLC bought a new stake in Natus Medical in the fourth quarter valued at $8,970,000. Finally, Renaissance Technologies LLC bought a new stake in Natus Medical in the fourth quarter valued at $6,733,000. Hedge funds and other institutional investors own 95.83% of the company’s stock.
A number of equities research analysts have issued reports on BABY shares. Zacks Investment Research cut Natus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. BidaskClub cut Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 6th. William Blair cut Natus Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, January 8th. Benchmark reiterated a “buy” rating and issued a $49.00 target price (down from $55.00) on shares of Natus Medical in a research note on Tuesday, January 16th. Finally, Roth Capital set a $39.00 target price on Natus Medical and gave the company a “buy” rating in a research note on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Natus Medical currently has a consensus rating of “Hold” and an average target price of $44.33.
BABY stock opened at $35.05 on Tuesday. The company has a current ratio of 3.32, a quick ratio of 2.54 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $1,162.27, a price-to-earnings ratio of 24.17 and a beta of 0.47. Natus Medical Inc has a 1 year low of $28.00 and a 1 year high of $43.60.
Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.54 by ($0.12). The company had revenue of $131.40 million during the quarter, compared to the consensus estimate of $131.38 million. Natus Medical had a negative net margin of 4.05% and a positive return on equity of 11.36%. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.51 earnings per share. analysts predict that Natus Medical Inc will post 1.63 EPS for the current year.
Natus Medical declared that its Board of Directors has approved a share repurchase plan on Thursday, February 22nd that allows the company to buyback $30.00 million in outstanding shares. This buyback authorization allows the medical equipment provider to purchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its shares are undervalued.
In other news, Director Ken Ludlum sold 4,000 shares of the firm’s stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $31.68, for a total transaction of $126,720.00. Following the transaction, the director now directly owns 93,825 shares of the company’s stock, valued at $2,972,376. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Natus Medical Inc (BABY) Shares Sold by Metropolitan Life Insurance Co. NY” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/17/natus-medical-inc-baby-shares-sold-by-metropolitan-life-insurance-co-ny.html.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.